No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LEGN Legend Biotech
- 55.900
- +1.910+3.54%
Close Jul 16 16:00 ET
- 56.020
- +0.120+0.21%
Pre 09:14 ET
10.19BMarket Cap-21666P/E (TTM)
57.820High54.270Low1.68MVolume54.470Open53.990Pre Close94.24MTurnover2.11%Turnover RatioLossP/E (Static)182.28MShares77.30052wk High8.75P/B4.46BFloat Cap38.60052wk Low--Dividend TTM79.77MShs Float77.320Historical High--Div YieldTTM6.58%Amplitude23.410Historical Low56.027Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Legend Biotech's Preliminary CARVYKTI Sales Report
Express News | Legend Biotech Corp -Announced Carvykti Generated About $186 Mln in Net Trade Sales During the Quarter Ended June 30, 2024
J&J Beats in Q2 as Pharma Segment Outperforms
Hong Kong stock market news | Genscript Bio (01548) fell more than 4%, with a total market value of over 25 billion Hong Kong dollars. Reports suggest that Legend Biotech may have received a takeover offer.
Genscript Bio (01548) fell more than 4%, and as of press time, it fell by 3.67% to HKD 12.08, with a turnover of 0.168 billion HKD, and a total market value exceeding 25 billion HKD.
The Latest Analyst Ratings For Legend Biotech
In the preceding three months, 15 analysts have released ratings for Legend Biotech (NASDAQ:LEGN), presenting a wide array of perspectives from bullish to bearish.The table below summarizes their
TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating
Legend Biotech (LEGN) has an average rating of outperform and price targets ranging from $60 to $95, according to analysts polled by Capital IQ.Price: 53.44, Change: -0.93, Percent Change: -1.71
Comments
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
7
🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
$Supernus Pharmaceuticals(SUPN.US$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US$ & $Johnson & Johnson(JNJ.US$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US$ & $Bristol-Myers Squibb(BMY.US$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US$...
11
2
$Legend Biotech(LEGN.US$
waiting patiently for fda 😌🙏✨
waiting patiently for fda 😌🙏✨
1
🗓️ Last week’s PDUFAs:
$Akebia Therapeutics(AKBA.US$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co(MRK.US$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals(REGN.US$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca(AZN.US$ : 🤔
⇒...
$Akebia Therapeutics(AKBA.US$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co(MRK.US$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca(AZN.US$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals(REGN.US$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca(AZN.US$ : 🤔
⇒...
8
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
